The US Food and Drug Administration has substantially increased the number of potential coronavirus treatments being tested in less than three weeks, and saw a more than 10-fold jump in the number in planning stages.
The agency’s Coronavirus Treatment Acceleration Program (CTAP) reported that as of 19 April there were 72 active clinical trials for therapeutic agents and another 211 development programs in the planning stages